前列腺癌MTS_1-P_(16)与突变P_(53)的表达研究

Expression of MTS_1-P_(16) and Mutant P_(53) in Prostate Carcinoma

应用单克隆抗体(MTS_1-P_(16(C-20))、PAb-DO-1-P_(53)免疫组化技术对38例高、中、低三种不同分化的前列腺癌MTS_1-P_(16)与突变P_(53)的表达率进行了比较研究。结果显示:在高、中、低三种不同分化的前列腺癌组织切片中MTS_1-P_(16)的阳性表达率为46.2％、21.4％和10％:突变P_(53)的阳性表达率为38.5％、71.4％和72.7％。MTS_1-P_(16)与突变P_(53)总的阳性表达率为23.6％和60.5％。结果提示:MTS_1-P_(16)的表达率随细胞分化恶化而丢失;突变P_(53)随细胞分化恶化表达率升高,MTS_1-P_(16)与P_(53)的丢失、突变与过度表达与肿瘤的发生及恶性生物学行为有关,同时测定MTS_1-P_(16)与突变P_(53)可作为评价前列腺癌预后新的生物学指标。

Immunohistochemical technique with monoclonal antibody (MTS1-P16. PAb-DO-1-P53) was used to study the expression of MTS1-P16 and mutant P53 tumor suppresser gene in paraffin embedded tissues of 38 cases of prostate cancer. The positive expression rates of MTS1-P16 were 46. 2% (6/13). 21. 4%(3/ 14) and 10%(1/11) in the well-differentiated, the moderate differentiated and the poorly differentiated prostate carcinoma respectively. The mutant P53 expression rates were 38. 7% (5/13), 71. 4% (10/14) and 72. 7% (8/11) in three differentiated prostate cancer respectively. Total positive expression rate of MTS1-P16 was 23. 6%. but the rate of P53 was 60. 5% (23/38) in all 38 cases of prostate carcinoma specimens. The results demonstrated that losses, mutant and over-expression of MTS1-P16 and P53 may be used as a new prognostic marker.